A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.